Recruiting Alzheimers Disease Studies in St. Petersburg
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)...
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that ha...
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head an...
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild t...
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or...
About Alzheimers Disease Clinical Trials in St. Petersburg
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 5 alzheimers disease clinical trials recruiting participants in St. Petersburg, FL. These studies are seeking a combined 2,180 participants. Research is being sponsored by GlaxoSmithKline, Genmab, Merus N.V. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in St. Petersburg — FAQ
Are there alzheimers disease clinical trials in St. Petersburg?
Yes, there are 5 alzheimers disease clinical trials currently recruiting in St. Petersburg, FL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in St. Petersburg?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the St. Petersburg research site will contact you about next steps.
Are clinical trials in St. Petersburg free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many St. Petersburg studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 5 active trials in St. Petersburg are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov